-
Zalicus a Potential Buy Out Target for Pfizer - SeekingAlpha
Monday, July 11, 2011 - 2:46pm -
Merck to Participate in New Research Efforts to Eradicate HIV
Monday, July 11, 2011 - 12:36pm | 56Merck (NYSE: MRK) today announced that company researchers will participate in two new collaborative efforts led by the prominent academic institutions of the University of North Carolina Chapel Hill and the University of California San Francisco to develop new approaches towards eradicating HIV,...
-
APAC, MRNA, JVA, LOCM Top NASDAQ Gainers July 8th
Monday, July 11, 2011 - 12:20pm | 435POINT ROBERTS - July 11, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, reports on top percentage gainers on the NASDAQ for July 08, 2011. APAC Customer Services, Inc. (NASDAQ: APAC) soared 53.85% to $101.20 on news it was to be acquired by One Equity...
-
LifeTech Capital Reiterates Buy and PT of $2.50 on NovaBay
Monday, July 11, 2011 - 9:21am | 42LifeTech Capital reiterated its Buy rating on NovaBay (NYSE: NBY). At the same time, the rating agency left its price target on the company's stock unchanged at $2.50. On Friday, NovaBay closed the day at $1.02.
-
Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
Monday, July 11, 2011 - 9:06am | 178Generex Biotechnology Corporation (OTC: GNBT) announced today the publication of studies conducted at the Mayo Clinic using the Antigen Express proprietary Ii-Key technology. Antigen Express, Inc., the Company's wholly-owned subsidiary, has used this technology platform in the development of self...
-
Citi Maintains Buy on Bristol-Myers Squibb
Monday, July 11, 2011 - 8:11am | 99Citi is out with its report today on Bristol-Myers Squibb (NYSE: BMY), maintaining Buy. In a note to clients, Citi writes, "We rate BMY stock Buy/Medium Risk (1M). BMY offers a strong stable of late-stage pipeline assets (Yervoy, Eliquis, Nnulogix, dapagliflozin, Orencia subcutaneous), which we...
-
Piper Jaffray Reports On VPHM In Advance Of 2Q:11 Results
Monday, July 11, 2011 - 8:06am | 113Piper Jaffray is maintaining its Overweight rating, along with its price target, set at $23, on ViroPharma (NASDAQ: VPHM) in light of expected 2Q:11 results. In the report, Piper Jaffray writes, “Another quarter has passed without generic competition for Vancocin. Adding a full 2Q:11 of Vancocin...
-
Sanofi Divests Dermik Dermatology Unit to Valeant Pharmaceuticals International for $425M
Monday, July 11, 2011 - 8:01am | 62Sanofi (NYSE: SNY) announced today the strategic divestiture of its dermatology business, Dermik, to Valeant Pharmaceuticals International Inc. (NYSE: VRX), for a total cash consideration of US $425 million. Valeant is a pharmaceutical company focused on the neurology and dermatology therapeutic...
-
Deutsche Bank Maintains Buy on Valeant Pharmaceuticals
Monday, July 11, 2011 - 7:24am | 85Deutsche Bank is out with its report today on Valeant Pharmaceuticals (NYSE: VRX), maintaining Buy after Valeant agreed to acquire Dermix. In a note to clients, Deutsche Bank writes, "Given the company's presence in dermatology in both the US and Canada, this appears to be a solid addition to...
-
Robert Jones Appointed President & CEO and to the Board of Directors of Acura Pharmaceuticals, Inc.
Monday, July 11, 2011 - 6:58am | 150Acura Pharmaceuticals, Inc. (Nasdaq: ACUR) announced today that Robert B. Jones has been appointed President and CEO. Mr. Jones had been serving in that capacity on an interim basis since May 2011, succeeding Andy Reddick who passed away on April 28, 2011. Additionally, Mr. Jones has been appointed...
-
Deutsche Bank Comments On Valeant's Acquisition Of Dermik
Monday, July 11, 2011 - 6:14am | 69This morning Deutsche Bank published a report stating, "Valeant agreed to acquire Dermik - the North American dermatology subsidiary of Sanofi as well as worldwide (ex-France) rights to facial aesthetic product Sculptra (estimated US sales of $32M) - for approximately $425M." Valeant (NYSE: VRX)...
-
Trending Stocks to Watch This Week
Sunday, July 10, 2011 - 11:38pm | 3980Now you can follow me on Stocktwits and Twitter! Each week I publish stocks to watch for the upcoming week as potential momentum trades or longer-term investments. The stocks below all have a 50k minimum average daily share volume and traded at a 52-week high on strong volume, with a minimum of...
-
Stocks to Watch for Monday 07/11/11: Fresh 52 Week Highs and Lows
Sunday, July 10, 2011 - 6:15pm | 2231Stocks trading at or near 52-week highs and lows provide excellent trading opportunities, as volatility tends to increase at such levels. The following stocks hit new 52-week highs in Friday's trading session (listed from highest total volume to lowest): 1) Melco Crown Entertainment (NASDAQ:...
-
Stocks Going Ex Dividend the Second Week of July
Saturday, July 9, 2011 - 11:57pm | 728Here is our latest update on the stock trading technique called 'Buying Dividends'. This is the process of buying stocks before the ex dividend date and selling the stock shortly after the ex date at about the same price, yet still being entitled to the dividend. This technique generally works only...
-
Earnings Ahead 07-08-2011
Friday, July 8, 2011 - 5:26pm | 837Cusick's Corner Buyers showed up at the close, and I am holding the long deltas in the S&Ps and short deltas in the bonds over the weekend. The thought process is that next week we have earnings plus the anticipation for solid numbers that could potentially start to drive the market early. The...